Indaptus Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Indaptus Therapeutics de winst en omzet met respectievelijk 12.9% en 85% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 31.7% per jaar.

Belangrijke informatie

12.9%

Groei van de winst

31.7%

Groei van de winst per aandeel

Biotechs winstgroei	27.0%
Inkomstengroei	85.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	16 Oct 2024

Recente toekomstige groei-updates

Recent updates

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Aug 15

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Aug 08

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Sep 29

Winst- en omzetgroeiprognoses

NasdaqCM:INDP - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-24	N/A	N/A	1
12/31/2025	N/A	-22	N/A	N/A	2
12/31/2024	N/A	-18	N/A	N/A	2
6/30/2024	N/A	-16	-13	-13	N/A
3/31/2024	N/A	-15	-12	-12	N/A
12/31/2023	N/A	-15	-13	-13	N/A
9/30/2023	N/A	-15	-13	-13	N/A
6/30/2023	N/A	-15	-14	-14	N/A
3/31/2023	N/A	-15	-15	-15	N/A
12/31/2022	N/A	-14	-13	-13	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-14	-15	-15	N/A
3/31/2022	N/A	-10	-14	-14	N/A
12/31/2021	N/A	-8	-11	-11	N/A
9/30/2021	N/A	-5	-9	-9	N/A
6/30/2021	N/A	-3	-4	-4	N/A
3/31/2021	N/A	-4	-4	-4	N/A
12/31/2020	N/A	-4	-3	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat INDP de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat INDP de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat INDP de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat INDP volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat INDP volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van INDP naar verwachting over 3 jaar hoog zal zijn

Indaptus Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 15% to US$15.00

Price target decreased to US$11.00

Recent updates

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven